Drug Profile

RP 14042

Alternative Names: RP-14042

Latest Information Update: 20 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rhizen Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase 7 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

09 Dec 2022 Rhizen Pharmaceuticals plans to file IND application for Solid tumours in first half of 2023 (Rhizen Pharmaceuticals pipeline, December 2022)
26 Oct 2022 Preclinical trials in Solid tumours in Switzerland (unspecified route)
26 Oct 2022 Pharmacodynamics and pharmacokinetics data from a preclinical trials in Solid tumours presented at the 34^thEORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com